- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02368704
Role of Endoplasmic Reticulum Stress in the Pathophysiology of Type 2 Diabetes (GLUCOSTRESS)
The purpose of this study is to investigate whether Endoplasmic Reticulum (ER) stress pathway is activated in peripheral tissues (adipose tissue) in insulin resistant diabetic patients compared to healthy subjects normoglycemic matched for age and sex an to investigate whether ER stress pathway can be activated in response to insulin. Indeed, some preliminar on rates studies shows that ER stress pathway is activated by insulin in liver and adipose tissue showing that hyperinsulinemia might help trigger stress path ER.
For this, we propose a case control study of type 2 diabetic patients vs control subjects in which markers of ER stress will be evaluated from abdominal subcutaneous adipose tissue obtained before and after euglycemic hyperinsulinemic. We chose to consider adipose tissue subcutaneous rather than visceral adipose tissue for obvious reasons of lesser invasiveness.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
-
Paris, France, 75010
- Saint-Louis Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Specific criteria for diabetic patients:
- Having type 2 diabetes for at least 6 months
- HbA1c ≤ 8%
- Treated by lifestyle and dietary rules associated or not to a hypoglycemic therapy (metformin and / or sulfamid) and / or insulin secretors dependent glucose as inhibitors of DPP4 (dipeptidyl peptidase-4): Vildagliptin, Sitagliptin, Saxagliptin
- No modification of hypoglycemic therapy and / or insulin secretors for at least 3 months
Specific criteria for control subjects:
- Nondiabetic subjects (fasting blood glucose <7.0 mmol / l without hypoglycemic treatment).
- The control subjects should be matched to patients for age (± 5 years), sex, and BMI (± 2 kg/m2).
Common criteria for patients and control subjects:
- Aged 18 to 60 years
- Body Mass Index between 25 and 35 kg/m2
- Accepting the constraints of the protocol and who signed the informed consent
- Systolic blood pressure < 160 mmHg, diastolic blood pressure < 90 mm Hg (with or without antihypertensive treatment)
- Resting heart rate between 55 and 100 beats/min.
- Normal laboratory tests or not clinically significant abnormality for NFS platelets, PT, aPTT, fibrinogen ALT, AST, GGT, Serum electrolytes, urea, creatinine, Uric acid Triglycerides, total cholesterol, HDL cholesterol
- HCG negative blood (for female subjects)
- Affiliated to the Social Security.
Exclusion Criteria:
- Current infections or recent infections (<10 days)
- Neoplastic disorders (with the exception of carcinoma in situ of the cervix or cutaneous epithelioma), haematological, cardiovascular, psychiatric, neurological
- Poisoning smoking (>10 cigarettes per day, what ever the duration of intoxication)
- Treatment with insulin or glitazones Pregnancy, Breastfeeding
- Body Mass Index > 35 kg/m2
- Any drug taken for less than 8 days without the inclusion of minor analgesics (aspirin, paracetamol), anti-hypertensive medications, oral hypoglycemic (metformin and sulphonylureas) and insulin secretors dependent glucose as inhibitors of DPP4 (dipeptidyl peptidase-4) and oral contraceptives.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: Cas-témoins
- Perspectives temporelles: Transversale
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
control
control subjects with :
|
|
|
case
Diabetic patients with :
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Show an increase in markers of ER stress in fasting patients with type 2 diabetes
Délai: 2 days
|
Protein expression markers of ER stress pathway BiP / GRP 78, CHOP, ATF4 EDEM and XBP-1
|
2 days
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Assess whether insulin induces an increase in markers of ER stress
Délai: 2 days
|
Insulin sensitivity
|
2 days
|
|
Insulin secretion in response to glucose infusion
Délai: 2 days
|
2 days
|
|
|
Insulin secretion in response to arginine infusion
Délai: 2 days
|
2 days
|
|
|
Lipolysis on insulin
Délai: 2 days
|
2 days
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- GLUCOSTRESS P 08 11 22
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .